MRA on GMP Inspections between Switzerland and Canada extended
On the Road to 30,000 Members
Let us become the World's Leading GMP/GDP Compliance Community in 2026
The Mutual Recognition Agreement (MRA on Medicinal Products: Drug GMP Compliance Certification, Sectoral Annex on GMP) between Switzerland and Canada on the GMP certification of medicinal products has been in force since 2000. The text has not been revised since then.
However, Health Canada and Swissmedic have now agreed to extend the existing approach of recognising GMP inspection results to include inspections carried out in countries outside the territories of the respective contracting parties. In addition, "stable" medicinal products derived from human blood or human plasma will be included. In addition, it was agreed to introduce processes for the exchange of information and compliance for product-specific on-site evaluations (OSE) by Health Canada and pre-approval inspections by Swissmedic.
Source: Swissmedic
Related GMP News
02.09.2026Deficiencies in Staffing, Monitoring and Aseptic Techniques – Warning Letter to a European Company
26.08.2026FDA Warning Letter: Inadequate Warehouse Controls and Lot Traceability
19.08.2026Poor Hygiene and Environmental Conditions - FDA Warning Letter
28.07.2026Pre-approval Inspections: FDA introduces New Guidance
22.07.2026Do you know about QPSHARE?